Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys

Psychopharmacology

Volumn 136, Issue 1, 1998, Pages 50-58

  Prendergast, Mark A ^a,b   Jackson, William J ^a   Terry Jr , Alvin V ^a   Decker, Michael W ^c   Arneric, Stephen P ^c   Buccafusco, Jerry J ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

( ) Nicotine; ABT 089; ABT 418; Cognition; Delay matching; Distractibility; Monkey

Indexed keywords

2 METHYL 3 (2 PYRROLLIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; NICOTINE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ACCURACY; ALERTNESS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOSE RESPONSE; ENANTIOMER; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RECALL;

ANIMALS; ANTI-ANXIETY AGENTS; ATTENTION; CHOLINERGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; ISOXAZOLES; MACACA MULATTA; MACACA NEMESTRINA; MALE; MENTAL RECALL; NICOTINE; NICOTINIC AGONISTS; PHOTIC STIMULATION; PYRIDINES; PYRROLIDINES; RECEPTORS, NICOTINIC;

EID: 0031882851     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050538     Document Type: Article

References (40)

1. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes M, Cadman ED, Adams P, Garvey DS, Wasicak J, Williams W (1994) ABT-418: a novel cholinergic ligand with cognition enhancing and anxiolytic activities I in vitro characterization. J Pharmacol Exp Ther 270: 310-318
2. Arneric SP, Anderson DJ, Bannon AW, Briggs CA, Buccafusco JJ, Brioni JD, Cannon JB, Decker MW, Donnelly-Roberts D, Gopalakrishnan M, Holladay MW, Kyncl J, Marsh KC, Pauly J, Radek RJ, Rodriques AD, Sullivan JP (1995a) Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev 1: 1-26
3. Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J, Williams M, Buccafusco JJ (1995b) Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alz Dis Assoc Disord 9: 50-61
4. Arnsten AFT, Contant TA (1992) Alpha-adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology 108: 159-169
5. Bartus RT, Dean RL (1979) Recent memory in aged non-human primates: hypersensitivity to visual interference during retention. Exp Aging Res 5: 386-400
6. Benowitz NL (1992) Nicotine and coronary heart disease. Trends Cardiovasc Med 1: 315-321
7. Benson DF (1991) The role of frontal dysfunction in attention deficit hyperactivity disorder. J Child Neurol 6: S9-S12
8. Broks P, Preston C, Traub P, Poppleton P, Ward D, Stahl SM (1988) Modeling dementia; effects of scopolamine on memory and attention. Neuropsychologia 28: 685-700
9. Buccafusco JJ, Jackson WJ (1991) Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12: 233-238
10. Buccafusco JJ, Jackson WJ, Terry AV Jr, Marsh KC, Decker MW, Arneric SP (1995) Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120: 256-266
11. Castellanos FX, Giedd JN, Eckburg P, Marsh WL, Vaituzis AC, Kaysen D, Hamburger SD, Rapoport JL (1994) Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. Am J Psychiatry 151: 1791-1796
12. Clark PBS, Pert A (1985) Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348: 355-358
13. Davis HP, Cohen A, Gandy M, Colombo P, VanDusseldorp G, Simolke N, Romano J (1990) Lexical priming deficits as a function of age. Behav Neurosci 104: 288-297
14. Decker MW, Brioni J, Sullivan JP, Buckley M, Radek R, Raskiewicz JL, Hughes M, Giardini W, Wasicak JT, Garvey DS, Williams M, Arneric SP (1994) ABT-418: a novel cholinergic ligand with cognition enhancing and anxiolytic activities. II. In vivo characterization. J Pharmacol Exp Ther 270: 319-328
15. Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin N-H, Li Y, Daanen J, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP (1996) Effects of ABT-089, a novel cholinergic channel modulator, on cognitive performance in rats and monkeys. Soc Neurosci Abstr 22: 1263
16. Elia J (1993) Drug treatment for hyperactive children. Therapeutic guidelines. Drugs 46: 863-871
17. Elrod K, Buccafusco JJ, Jackson WJ (1988) Nicotine enhances delayed matching-to-sample performance in primates. Life Sci 43: 277-287
18. Gadow K (1991) Effects of stimulant drugs on academic performance in hyperactive and learning disabled children. J Learn Disord 16: 190-199
19. Garvey DS, Wasicak JT, Decker MW, Brioni JD, Buckley JD, Sullivan JP, Carrera GM, Holladay MW, Arneric SP, Williams M (1994) Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J Med Chem 37: 1055-1059
20. Goldman-Rakic PS (1987) Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory In: Plum F (ed) Handbook of physiology: the nervous system, higher functions of the brain, sect 1, vol V, part 1. American Physiological Society, Bethesda, pp 373-417
21. Greenhill LL (1992) Pharmacologic treatment of attention deficit hyperactivity disorder. Ped Psychopharmacol 15: 1-27
22. Haikala H, Ahtee L (1988) Antagonisms of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine. Naunyn Schmiedeberg's Arch Pharmacol 338: 169-173
23. Hodges H, Allen Y, Sinden J, Mitchell SN, Arendt T, Lantos PL, Gray JA (1991) The effects of cholinergic drugs and cholinergic-rich foetal neural transplants on alcohol induced deficits in radial maze performance in rats. Behav Brain Res 43: 7-28
24. Hoyer WJ, Rebok GW, Sved MS (1979) Effects of varying irrelevant information on adult age differences in problem solving. J Gerontol 34: 553-560
25. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108: 485-494
26. Khosla S, Laddu A, Ehrenpreis S, Somberg JC (1994) Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking. Am Heart J 127: 1669-1672
27. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology 108: 417-431
28. Levin ED, Lee C, Rose JE, Reyes A, Ellison G, Jaravik M, Gritz E (1990) Chronic nicotine and withdrawal effects on radial-arm performance in rats. Behav Neurol Biol 53: 269-276
29. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J (1996) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123: 55-63
30. Lin N-H, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodriques AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW (1997) Structure-activity studies on 2-methyl-3-(2(s)-pyrrolidinylmethoxy)pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 40: 385-390
31. Mason ST, Fibiger HC (1978) Evidence for a role of brain noradrenaline in attention and stimulus sampling. Brain Res 159: 421-426
32. Morgan WW, Pfeil KA (1979) Mecamylamine blockade of nicotine enhanced noradrenaline turnover in rat brain. Life Sci 24: 417-420
33. Newhouse P, Sunderland T, Tariot P, Blumhardt C, Weingartner H, Mellow W (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95: 171-175
34. Newhouse PA, Potter A, Corwin J (1996) Acute administration of the cholinergic channel activator ABT-418 improves learning in Alzheimer's disease. Annual Conference of the Society for Research on Nicotine and Tobacco, Washington, DC
35. Papke RL, Thinschmidt JS, Moulton BA, Meyer ED, Poirier A (1997) Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br J Pharmacol 120: 429-438
36. Prendergast MA, Terry AV Jr, Jackson WJ, Marsh KC, Decker MW, Arneric SP, Buccafusco JJ (1997) Improvement in accuracy of delayed recall in aged and non-aged mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology 130: 276-284
37. Sahakian BJ, Jones G, Levy R, Gray J, Warburton, D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154: 797-800
38. Terry AV Jr, Buccafusco JJ, Jackson WJ (1993a) Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance by monkeys. Pharmacol Biochem Behav 45: 925-929
39. Terry AV Jr, Jackson WJ, Buccafusco JJ (1993b) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 3: 304-312
40. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG (1989) Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79: 157-164